Riverhead Capital Management’s aTyr Pharma ATYR Stock Holding History

Riverhead Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$20K	Buy	5,784 +93	+2%	+$343	﹤0.01%	1470
2019 Q2	$29K	Hold	5,691	–	–	﹤0.01%	1484
2019 Q1	$44K	Hold	5,691	–	–	﹤0.01%	1446
2018 Q4	$40K	Hold	5,691	–	–	﹤0.01%	1440
2018 Q3	$65K	Hold	5,691	–	–	﹤0.01%	1462
2018 Q2	$73K	Hold	5,691	–	–	﹤0.01%	1415
2018 Q1	$211K	Hold	5,691	–	–	0.01%	1044
2017 Q4	$279K	Hold	5,691	–	–	0.01%	932
2017 Q3	$402K	Hold	5,691	–	–	0.02%	686
2017 Q2	$275K	Hold	5,691	–	–	0.01%	796
2017 Q1	$279K	Hold	5,691	–	–	0.02%	689
2016 Q4	$171K	Hold	5,691	–	–	0.01%	770
2016 Q3	$253K	Sell	5,691 -31,374	-85%	-$1.36M	0.02%	632
2016 Q2	$22.4M	Buy	37,065 +8,652	+30%	+$402K	0.72%	20
2016 Q1	$1.57M	Sell	28,413 -1,257	-4%	-$95.6K	0.02%	580
2015 Q4	$4.08M	Hold	29,670	–	–	0.06%	373
2015 Q3	$4.26M	Hold	29,670	–	–	0.07%	329
2015 Q2	$7.69M	Buy	+29,670	New	+$9.21M	0.12%	254

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

Riverhead Capital Management's ATYR Position: Q3 2019 in Review

Riverhead Capital Management increased its aTyr Pharma (ATYR) stake by 1.6% in Q3 2019, buying an estimated $343 and bringing the position to 5,784 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

Riverhead Capital Management first reported a position in ATYR in Q2 2015 and has held it in 18 quarters since. The position peaked at $22.4M in Q2 2016. 19 funds tracked by Wall St. Rank hold ATYR as of Q3 2019.

Riverhead Capital Management held 5,784 shares of aTyr Pharma worth $20K as of Q3 2019.
Riverhead Capital Management bought 93 aTyr Pharma shares in Q3 2019, an estimated $343.
aTyr Pharma made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1470 holding.
Riverhead Capital Management first reported a position in aTyr Pharma in Q2 2015 and has held it in 18 quarters since.
Riverhead Capital Management's aTyr Pharma position peaked at $22.4M in Q2 2016.
19 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.